Second-line Chemotherapy for Advanced Bladder Cancer: Taxanes Versus Vinflunine

Second-line Chemotherapy for Advanced Bladder Cancer: Taxanes Versus Vinflunine

Aim: Second-line chemotherapy in advanced urothelial carcinoma (UC) remains a significant clinical challenge, with limited high-level evidence guiding regimen selection. Vinflunine is the only agent approved by the European Medicines Agency for this setting, while taxanes are widely used off-label b...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bilgin Demir, Ali Aytaç, Gökhan Çolak, Onur Yazdan Balçık, Ömer Acar
Format:	Article
Language:	English
Published:	Galenos Publishing House 2025-08-01
Series:	Acta Haematologica Oncologica Turcica
Subjects:	urothelial carcinoma second-line chemotherapy taxanes vinflunine
Online Access:	https://www.actaoncologicaturcica.com/articles/second-line-chemotherapy-for-advanced-bladder-cancer-taxanes-versus-vinflunine/doi/ahot.galenos.2025.2025-7-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bladder cancer. A retrospective analysis of the use of vinfluvin in real clinical practice
by: A. S. Zhabina, et al.
Published: (2021-06-01)

Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
by: Toshihiko Matsumoto, et al.
Published: (2025-08-01)

Taxanes in adjuvant and neoadjuvant therapy for breast cancer
by: S. V. Limareva
Published: (2014-08-01)

Modern approaches to drug therapy of bladder cancer after first progression.
by: L. V. Bolotina, et al.
Published: (2015-06-01)

Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy studyResearch in context
by: Indra A. Van Assche, et al.
Published: (2024-12-01)

Establishment and Genetic Profiling of Platinum/Taxane Doublet-Resistant Cells Generated by Hybridizing Single Resistant Cells
by: Seiji Isonishi, et al.
Published: (2022-09-01)

Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study
by: Árpád Kézdi, et al.
Published: (2025-04-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

CNA landscape of HER2-negative breast cancer during administration of taxane-containing schemes of neoadjuvant chemotherapy
by: M. K. Ibragimova, et al.
Published: (2025-04-01)

MicroRNA-dependent mechanisms of taxane resistance in breast cancer
by: V. S. Apollonova, et al.
Published: (2022-12-01)

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial
by: Elena López-Miranda, et al.
Published: (2025-08-01)

Taxane-Producing Fungi Isolated from <i>Taxus globosa</i> Tree Bark
by: Jocelyn Guadalupe Guevara-Sánchez, et al.
Published: (2025-01-01)

Enhancement of taxane production in cell suspension culture of Corylus avellana L. Kalınkara by elicitation and precursor feeding
by: Ilayda Goktepe-Atilgan, et al.
Published: (2023-03-01)

Choice of adjuvant drug therapy on the basis of the molecular classification of breast cancer
by: N. S. Besova
Published: (2014-07-01)

EPHA5 and SOD2 genetic variants and their link to neurofilament light chain: early detection of taxane-induced neurotoxicity in Egyptian breast cancer patients
by: Amira B. Kassem, et al.
Published: (2025-06-01)

How Accurately Can Urologists Predict Eligible Patients for Immediate Postoperative Intravesical Chemotherapy in Bladder Cancer?
by: Hüseyin Alperen Yıldız, et al.
Published: (2025-07-01)

Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
by: Yichao Du, et al.
Published: (2025-08-01)

Experience of using chemotherapy treatment for the first recurrence of ovarian cancer
by: V. N. Zhurman
Published: (2025-01-01)

FAERS based disproportionality analysis and network pharmacology investigation of taxanes associated drug induced liver injury
by: Yijie Cheng, et al.
Published: (2025-04-01)

Primary urothelial carcinoma of an ileal conduit; six decades after childhood bladder exstrophy surgery: a rare and late complication
by: Areeba Ahmed, et al.
Published: (2025-05-01)

A Prospective Comparison of Subjective Symptoms and Neurophysiological Findings in the Assessment of Neuropathy in Cancer Patients
by: Vera Elisabeth Adreana Kleinveld, et al.
Published: (2024-12-01)

Second Renal Transplantation With Simultaneous Ileal Conduit Creation Following Transplant Nephroureterectomy and Native Cystectomy
by: Ayato Ito, et al.
Published: (2025-07-01)

Case Report: A comprehensive case study on aggressive high-grade urothelial carcinoma of bladder that transforms into enteric-type adenocarcinoma along with an integrated treatment approach
by: Neha Rahul, et al.
Published: (2025-06-01)

Immunohistochemical Expression of COX2 in Urothelial Carcinoma of the urinary bladder
by: Shayan Khattab Omer, et al.
Published: (2024-12-01)

Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy
by: Min Woo Hwang, et al.
Published: (2024-10-01)

Case Report: Metachronous bilateral upper tract and bladder urothelial carcinoma: a long-term follow-up [version 2; peer review: 1 approved, 2 approved with reservations]
by: Sahat Matondang, et al.
Published: (2023-06-01)

Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report
by: Kosuke Fukuda, et al.
Published: (2022-04-01)

POSSIBILITIES OF ORGAN-PRESERVING TREATMENT OF PATIENTS WITH MULTIPNEOADJUVANT COMBINATION CHEMOTHERAPY IN A PATIENT WITH CERVICAL CANCER IIIB STAGE WITH THE USE OF INTRA-ARTERIAL ADMINISTRATION OF PLATINUM DRUGS
by: A. G. Rerberg, et al.
Published: (2017-06-01)

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development
by: Whi-An Kwon, et al.
Published: (2025-01-01)

Current Status and Future Perspectives of Immunotherapies in Bladder Cancer
by: Gökhan Çolak, et al.
Published: (2025-08-01)

Second-line chemotherapy rechallenge in lung cancer patients: a Moroccan real-world study
by: Hassan Abdelilah Tafenzi, et al.
Published: (2025-05-01)

Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study
by: Soumya Mondal, et al.
Published: (2022-05-01)

Immunohistochemical expression of GATA3 in urothelial carcinoma of urinary bladder
by: Shadan Abdulkhaliq Jaf, et al.
Published: (2024-12-01)

[Cost Evaluation of First-Year Treatment for Locally Advanced or Metastatic Urothelial Carcinoma with Chemotherapy Plus Avelumab vs Chemotherapy Plus Best Supportive Care: A Cost of Care Model]
by: Daniela Paola Roggeri, et al.
Published: (2025-08-01)

Pediatric papillary urothelial neoplasm: 18-year single-center experience in diagnosis and treatment
by: Pei Liu, et al.
Published: (2025-06-01)

Crystal structures of (±)-(1SR,5SR,6SR,7SR,10SR,11SR,13RS,14SR,15SR,16RS)-13-acetoxy-16-benzyloxy-15-hydroxy-7-methoxymethoxy-3-oxo-11,15,18,18-tetramethyl-2,4-dioxatetracyclo[12.3.1.01,5.06,11]octadecan-10-yl benzoate and its 13-epimer
by: Takeshi Oishi, et al.
Published: (2025-01-01)

Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer
by: Shuo Wang, et al.
Published: (2024-11-01)

FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma
by: Yu Ishizuya, et al.
Published: (2025-02-01)

Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort
by: Aldéric Fraslin, et al.
Published: (2025-05-01)

The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary
by: A. G. Manikhas, et al.
Published: (2016-09-01)